0001557376 2025-11-01 2026-04-30 0001557376 2026-06-12 0001557376 2026-04-30 0001557376 2025-10-31 0001557376 us-gaap:SeriesCPreferredStockMember 2026-04-30 0001557376 us-gaap:SeriesCPreferredStockMember 2025-10-31 0001557376 2026-02-01 2026-04-30 0001557376 2025-02-01 2025-04-30 0001557376 2024-11-01 2025-04-30 0001557376 us-gaap:CommonStockMember 2025-01-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0001557376 us-gaap:RetainedEarningsMember 2025-01-31 0001557376 2025-01-31 0001557376 us-gaap:CommonStockMember 2026-01-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2026-01-31 0001557376 us-gaap:RetainedEarningsMember 2026-01-31 0001557376 2026-01-31 0001557376 us-gaap:CommonStockMember 2024-10-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001557376 us-gaap:RetainedEarningsMember 2024-10-31 0001557376 2024-10-31 0001557376 us-gaap:CommonStockMember 2025-10-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2025-10-31 0001557376 us-gaap:RetainedEarningsMember 2025-10-31 0001557376 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2025-02-01 2025-04-30 0001557376 us-gaap:RetainedEarningsMember 2025-02-01 2025-04-30 0001557376 us-gaap:CommonStockMember 2026-02-01 2026-04-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2026-02-01 2026-04-30 0001557376 us-gaap:RetainedEarningsMember 2026-02-01 2026-04-30 0001557376 us-gaap:CommonStockMember 2024-11-01 2025-04-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-04-30 0001557376 us-gaap:RetainedEarningsMember 2024-11-01 2025-04-30 0001557376 us-gaap:CommonStockMember 2025-11-01 2026-04-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2025-11-01 2026-04-30 0001557376 us-gaap:RetainedEarningsMember 2025-11-01 2026-04-30 0001557376 us-gaap:CommonStockMember 2025-04-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001557376 us-gaap:RetainedEarningsMember 2025-04-30 0001557376 2025-04-30 0001557376 us-gaap:CommonStockMember 2026-04-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0001557376 us-gaap:RetainedEarningsMember 2026-04-30 0001557376 zeox:LargeMedicalPracticeGroupAndDistributorMember 2025-11-01 2026-04-30 0001557376 zeox:LargeMedicalPracticeGroupAndDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0001557376 zeox:AnotherLargeMedicalPracticeGroupAndDistributorMember 2025-11-01 2026-04-30 0001557376 zeox:AnotherLargeMedicalPracticeGroupAndDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0001557376 zeox:LargeDistributorMember 2024-11-01 2025-04-30 0001557376 zeox:LargeDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001557376 zeox:AnotherLargeDistributorMember 2024-11-01 2025-04-30 0001557376 zeox:AnotherLargeDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001557376 zeox:TwoIndividualMedicalPracticesMember 2024-11-01 2025-04-30 0001557376 zeox:TwoIndividualMedicalPracticesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-04-30 0001557376 zeox:CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember 2025-11-01 2026-04-30 0001557376 zeox:CommonSharesUnissuedSharesOfRestrictedStockMember 2025-11-01 2026-04-30 0001557376 us-gaap:ConvertibleDebtSecuritiesMember 2025-11-01 2026-04-30 0001557376 zeox:CommonSharesIssuableUponTheFuturePaymentsMember 2025-11-01 2026-04-30 0001557376 zeox:CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember 2024-11-01 2025-04-30 0001557376 zeox:CommonSharesUnissuedSharesOfRestrictedStockMember 2024-11-01 2025-04-30 0001557376 us-gaap:ConvertibleDebtSecuritiesMember 2024-11-01 2025-04-30 0001557376 zeox:FinanceLeaseEquipmentMember 2026-04-30 0001557376 zeox:FinanceLeaseEquipmentMember 2025-10-31 0001557376 zeox:ManufacturingEquipmentMember 2026-04-30 0001557376 zeox:ManufacturingEquipmentMember 2025-10-31 0001557376 zeox:SalesRepresentativeAgreementMember 2026-02-01 2026-04-30 0001557376 zeox:SalesRepresentativeAgreementMember 2025-11-01 2026-04-30 0001557376 zeox:SalesRepresentativeAgreementMember 2025-02-01 2025-04-30 0001557376 zeox:SalesRepresentativeAgreementMember 2024-11-01 2025-04-30 0001557376 zeox:LeaseAgreementMember 2025-04-30 0001557376 zeox:LeaseAgreementMember 2025-04-01 2025-04-30 0001557376 zeox:LeaseAgreementMember 2025-06-30 0001557376 zeox:LeaseAgreementMember 2025-06-01 2025-06-30 0001557376 zeox:ManagementServicesOrganizationMember 2026-02-01 2026-04-30 0001557376 zeox:ManagementServicesOrganizationMember 2025-02-01 2025-04-30 0001557376 zeox:ManagementServicesOrganizationMember 2025-11-01 2026-04-30 0001557376 zeox:ManagementServicesOrganizationMember 2024-11-01 2025-04-30 0001557376 zeox:SalesAgreementMember 2025-02-01 2025-04-30 0001557376 zeox:SalesAgreementMember 2024-11-01 2025-04-30 0001557376 zeox:ConvertiblePromissoryNotesMember 2025-11-01 2026-04-30 0001557376 zeox:ConvertiblePromissoryNotesMember 2026-04-30 0001557376 zeox:ConvertiblePromissoryNotesMember 2026-02-01 2026-04-30 0001557376 zeox:ConvertiblePromissoryNotesMember 2025-02-01 2025-04-30 0001557376 zeox:ConvertiblePromissoryNotesMember 2024-11-01 2025-04-30 0001557376 zeox:N2021PlanMember 2021-09-01 2021-09-30 0001557376 zeox:N2021PlanMember 2023-06-01 2023-06-06 0001557376 zeox:N2021PlanMember 2026-06-01 2026-06-10 0001557376 zeox:N2021PlanMember 2026-04-30 0001557376 us-gaap:InvestorMember zeox:SubscriptionAgreementMember 2025-07-01 2025-07-25 0001557376 zeox:SubscriptionAgreementMember 2024-11-01 2025-10-31 0001557376 zeox:SubscriptionAgreementMember 2025-10-28 2025-11-02 0001557376 zeox:SubscriptionAgreementMember 2026-02-01 2026-02-10 0001557376 zeox:SubscriptionAgreementMember 2025-11-01 2026-04-30 0001557376 zeox:EightInvestorsMember 2025-11-01 2026-04-30 0001557376 zeox:ConsultantMember zeox:ConsultingAgreementMember 2025-11-30 2025-12-01 0001557376 zeox:ConsultantMember zeox:ConsultingAgreementMember 2025-12-01 0001557376 zeox:ConsultantMember zeox:ConsultingAgreementMember 2026-02-01 2026-04-30 0001557376 zeox:ConsultantMember zeox:ConsultingAgreementMember 2025-11-01 2026-04-30 0001557376 zeox:EmployeeMember zeox:N2021IncentiveStockPlanMember 2025-12-02 2025-12-23 0001557376 zeox:EmployeeMember zeox:N2021IncentiveStockPlanMember 2025-12-23 0001557376 zeox:EmployeeMember zeox:N2021IncentiveStockPlanMember 2026-02-01 2026-04-30 0001557376 zeox:EmployeeMember zeox:N2021IncentiveStockPlanMember 2025-11-01 2026-04-30 0001557376 zeox:IanBothwellMember srt:ChiefExecutiveOfficerMember zeox:N2021PlanMember 2026-01-01 2026-01-14 0001557376 zeox:DrGeorgeShapiroMember zeox:ChiefMedicalOfficerMember zeox:N2021PlanMember 2026-01-01 2026-01-14 0001557376 zeox:GreytVenturesLLCMember zeox:N2021PlanMember 2026-01-01 2026-01-14 0001557376 zeox:N2021PlanMember 2026-01-01 2026-01-14 0001557376 zeox:N2021PlanMember 2026-01-14 0001557376 zeox:N2021PlanMember 2026-02-01 2026-04-30 0001557376 zeox:N2021PlanMember 2025-11-01 2026-04-30 0001557376 zeox:DrKisidayMember zeox:N2021PlanMember zeox:EmploymentAgreementMember 2026-01-01 2026-01-14 0001557376 zeox:DrKisidayMember zeox:N2021PlanMember zeox:EmploymentAgreementMember 2026-01-14 0001557376 zeox:ConsultantMember 2026-02-01 2026-04-30 0001557376 zeox:ConsultantMember srt:MinimumMember 2026-04-30 0001557376 zeox:ConsultantMember srt:MaximumMember 2026-04-30 0001557376 zeox:ConsultantMember 2025-11-01 2026-04-30 0001557376 zeox:RestrictedStockAwardsMember 2026-04-30 0001557376 zeox:UnvestedRestrictedStockMember 2025-10-31 0001557376 zeox:UnvestedRestrictedStockMember 2025-11-01 2026-04-30 0001557376 zeox:UnvestedRestrictedStockMember 2026-04-30 0001557376 us-gaap:StockOptionMember 2025-10-31 0001557376 us-gaap:StockOptionMember 2025-11-01 2026-04-30 0001557376 us-gaap:StockOptionMember 2026-04-30 0001557376 zeox:EmployeesMember 2025-11-01 2026-04-30 0001557376 us-gaap:StockOptionMember 2026-02-01 2026-04-30 0001557376 us-gaap:StockOptionMember 2025-02-01 2025-04-30 0001557376 us-gaap:StockOptionMember 2024-11-01 2025-04-30 0001557376 us-gaap:WarrantMember 2026-02-01 2026-04-30 0001557376 us-gaap:WarrantMember 2025-02-01 2025-04-30 0001557376 us-gaap:WarrantMember 2025-11-01 2026-04-30 0001557376 us-gaap:WarrantMember 2024-11-01 2025-04-30 0001557376 us-gaap:WarrantMember 2026-04-30 0001557376 us-gaap:WarrantMember 2025-10-31 0001557376 zeox:DrKisidayMember zeox:N2021IncentiveStockPlanMember zeox:EmploymentAgreementMember 2026-01-01 2026-01-23 0001557376 zeox:SupplyAgreementMember 2026-04-30 0001557376 zeox:SupplyAgreementMember 2025-10-31 0001557376 zeox:HowardGolubMember 2024-11-01 2024-11-19 0001557376 zeox:TwoInvestorsMember us-gaap:SubsequentEventMember 2026-05-01 2026-06-15 iso4217:USD shares iso4217:USD shares pure zeox:Integer false 2026 Q2 --10-31 0001557376

10-Q true 2026-04-30 false 000-55008 Zeo ScientifiX, Inc. NV 47-4180540 3321 College Avenue Suite 246 Davie FL 33314 888 963-7881 Yes Yes Non-accelerated Filer true false false 7837441

1846000

221000

276000

35000

458000

279000

686000

423000

3266000

958000

609000

569000

11000

3886000

1527000

2143000

1980000

33000

3000

7000

247000

243000

17000 19000

671000

598000

3111000

2873000

63000 77000

3174000

2950000

0.001

100

0.001

2500000000

7787441

6747441

8000

7000

69435000

66304000

-68731000

-67734000

712000

-1423000

3886000

1527000

30000 43000 30000 75000

2581000

1149000

4027000

2239000

526000

256000

807000

447000

2055000

893000

3220000

1792000

2567000

2287000

4610000

4439000

-512000

-1394000

-1390000

-2647000

-390000 -390000

11000

21000

20000

43000

17000 -2000

5000

24000

21000

56000

-145000

-1391000

-997000

-2634000

-0.02

-0.22

-0.14

-0.42

7757469

6344817

7383436

6344817

6000

61645000

-63456000

-1805000

21000 21000 265000 265000 810000 810000

-1391000

6344817

6000

62741000

-64847000

-2100000

7614941

8000

68195000

-68586000

-383000

162500 650000 650000 10000 581000 581000 9000 9000

-145000

7787441

8000

69435000

-68731000

712000

6344817

6000

60554000

-62213000

-1653000

53000 53000 514000 514000 1620000 1620000

-2634000

6344817

6000

62741000

-64847000

-2100000

6747441

7000

66304000

-67734000

-1423000

487500 1950000 1950000 552500 1000 772000 773000 194000 194000 215000 215000

-997000

7787441

8000

69435000

-68731000

712000

-997000

-2634000

38000

34000

4000 12000

1182000

2187000

-390000 -2000

241000

-183000

-2000

179000

-3000

313000

2000

227000

165000

-11000

73000

-28000

-609000

-78000

78000

376000

298000

1950000

14000 37000

1936000

-37000

1625000

-115000

221000

657000

1846000

542000

50000

14000

125000

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Zeo ScientifiX, Inc. (“ZEO” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada under the name Bespoke Tricycles Inc. (changed to Biotech Products Services and Research, Inc. during September 2015 and to Organicell Regenerative Medicine, Inc., effective June 20, 2018). Effective February 20, 2024, we further amended our Articles of Incorporation to assume our current name, Zeo ScientifiX, Inc. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. In connection with the state of Florida’s new “stem cell therapy” law, effective July 1, 2025 (“SB 1768”), and the addition of several other states that are enacting similar legislation, the Company has begun to pursue clinical research and commercial sales strategies that are compliant with these new legislative measures. The Company has a portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes and Whartons Jelly matrix. The Company’s principal product is Zofin™, a product derived from amniotic fluid and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles. ZEO also manufactures Patient Pure X™ (“PPX™”), a proprietary autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood. ZEO’s products are all manufactured in FDA-registered, cGMP-compliant laboratory facilities. Our portfolio of products (“RAAM Products”) and related services are principally used in the health care industry administered through doctors and clinics (“Providers”). In addition to the Company’s efforts to now supply products that are compliant with newly enacted state stem cell legislation, the Company has recently developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. In the opinion of management, the condensed unaudited consolidated financial statements contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of April 30, 2026, the results of its operations for the three months and six months ended April 30, 2026 and 2025 and the cash flows for the six months ended April 30, 2026 and 2025. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities Exchange Commission, although we believe that the disclosures made are adequate to make the information not misleading. These unaudited consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended October 31, 2025 filed with the Securities and Exchange Commission. All amounts presented have been rounded to the nearest thousand except share amounts, share prices and earnings per share. Concentrations of Risk Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At April 30, 2026, the Company had $884,000 of cash balances in one financial institution in excess of FDIC insurance coverage limits and $347,000 of cash balances in another financial institution in excess of FDIC insurance coverage limits. Major Customer During the six months ended April 30, 2026, the Company sold products and services totaling approximately $571,000 <span id="xdx_902_ecustom--ConcentrationRiskThresholdPercentage_c20251101__20260430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeMedicalPracticeGroupAndDistributorMember_pd" title="Concentration percentage">(14.2%) to a large medical practice group and distributor and approximately $511,000 <span id="xdx_902_ecustom--ConcentrationRiskThresholdPercentage_c20251101__20260430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeMedicalPracticeGroupAndDistributorMember_pd" title="Concentration percentage">(12.7%) to another large medical practice group and distributor. During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 <span id="xdx_90C_ecustom--ConcentrationRiskThresholdPercentage_c20241101__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_pd" title="Concentration percentage">(12.1%) to a large distributor and $341,000 <span id="xdx_900_ecustom--ConcentrationRiskThresholdPercentage_c20241101__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pd" title="Concentration percentage">(15.2%) and $228,000 <span id="xdx_908_ecustom--ConcentrationRiskThresholdPercentage_c20241101__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoIndividualMedicalPracticesMember_pd" title="Concentration percentage">(10.2%) to two individual medical practices. The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity. Revenue Recognition The Company follows the guidance of the Financial Accounting Standards Board (“FASB’) Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet. Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share are calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments. At April 30, 2026, the Company had <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">4,649,857 common shares issuable upon the exercise of options and warrants (vested and unvested), <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesUnissuedSharesOfRestrictedStockMember_z44jNRyU8gdf" title="Antidilutive securities excluded from computation of earnings per share">295,000 unissued shares of restricted stock, $<span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pd" title="Antidilutive securities excluded from computation of earnings per share">250,000 of convertible debt securities (convertible into a maximum of 41,667 shares) and $<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheFuturePaymentsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">50,000 of future obligations in connection with the purchase of the BioLumina assets that may be settled through the issuance of common stock (convertible into a maximum of 20,000 shares) that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the three months ended April 30, 2026. At April 30, 2025, the Company had <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">3,591,721 common shares issuable upon the exercise of options and warrants (vested and unvested), <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesUnissuedSharesOfRestrictedStockMember_zrYVICl4YiQ9" title="Antidilutive securities excluded from computation of earnings per share">228,333 unissued restricted stock and $<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pd" title="Antidilutive securities excluded from computation of earnings per share">725,000 of convertible debt securities that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the six months ended April 30, 2025. Stock-Based Compensation All stock-based payments are recognized in the financial statements based on their fair values. The Company periodically issues stock options and stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods. Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $31,000 and $42,000 for the three months ended April 30, 2026 and 2025, respectively and approximately $50,000 and $48,000 for the six months ended April 30, 2026 and 2025, respectively. The research and development costs primarily relate to the filing and approval of IND applications and the performance of clinical trials. Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one — Quoted market prices in active markets for identical assets or liabilities; Level two — Inputs other than level one inputs that are either directly or indirectly observable such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level three — Unobservable inputs that are supported by little or no market activity and developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of convertible notes approximate their fair values because interest rates on these obligations are based on prevailing market interest rates. Recently Issued Accounting Pronouncements In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on its financial statement disclosures. We have reviewed all accounting pronouncements recently issued by the FASB and the SEC. The authoritative pronouncements that we have already adopted did not have a material effect on our financial condition, results of operations, cash flows or reporting thereof, and except as otherwise noted above, we do not believe that any of the authoritative pronouncements that we have not yet adopted will have a material effect upon our financial condition, results of operations, cash flows or reporting thereof.

Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. In the opinion of management, the condensed unaudited consolidated financial statements contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of April 30, 2026, the results of its operations for the three months and six months ended April 30, 2026 and 2025 and the cash flows for the six months ended April 30, 2026 and 2025. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities Exchange Commission, although we believe that the disclosures made are adequate to make the information not misleading. These unaudited consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended October 31, 2025 filed with the Securities and Exchange Commission. All amounts presented have been rounded to the nearest thousand except share amounts, share prices and earnings per share.

Concentrations of Risk Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At April 30, 2026, the Company had $884,000 of cash balances in one financial institution in excess of FDIC insurance coverage limits and $347,000 of cash balances in another financial institution in excess of FDIC insurance coverage limits. Major Customer During the six months ended April 30, 2026, the Company sold products and services totaling approximately $571,000 <span id="xdx_902_ecustom--ConcentrationRiskThresholdPercentage_c20251101__20260430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeMedicalPracticeGroupAndDistributorMember_pd" title="Concentration percentage">(14.2%) to a large medical practice group and distributor and approximately $511,000 <span id="xdx_902_ecustom--ConcentrationRiskThresholdPercentage_c20251101__20260430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeMedicalPracticeGroupAndDistributorMember_pd" title="Concentration percentage">(12.7%) to another large medical practice group and distributor. During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 <span id="xdx_90C_ecustom--ConcentrationRiskThresholdPercentage_c20241101__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_pd" title="Concentration percentage">(12.1%) to a large distributor and $341,000 <span id="xdx_900_ecustom--ConcentrationRiskThresholdPercentage_c20241101__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pd" title="Concentration percentage">(15.2%) and $228,000 <span id="xdx_908_ecustom--ConcentrationRiskThresholdPercentage_c20241101__20250430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoIndividualMedicalPracticesMember_pd" title="Concentration percentage">(10.2%) to two individual medical practices. The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products.

250000

884000

571000

-0.142

511000

-0.127

270000

-0.121

341000

-0.152

228000

-0.102

Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity.

Revenue Recognition The Company follows the guidance of the Financial Accounting Standards Board (“FASB’) Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet.

Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share are calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments. At April 30, 2026, the Company had <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">4,649,857 common shares issuable upon the exercise of options and warrants (vested and unvested), <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesUnissuedSharesOfRestrictedStockMember_z44jNRyU8gdf" title="Antidilutive securities excluded from computation of earnings per share">295,000 unissued shares of restricted stock, $<span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pd" title="Antidilutive securities excluded from computation of earnings per share">250,000 of convertible debt securities (convertible into a maximum of 41,667 shares) and $<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheFuturePaymentsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">50,000 of future obligations in connection with the purchase of the BioLumina assets that may be settled through the issuance of common stock (convertible into a maximum of 20,000 shares) that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the three months ended April 30, 2026. At April 30, 2025, the Company had <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">3,591,721 common shares issuable upon the exercise of options and warrants (vested and unvested), <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesUnissuedSharesOfRestrictedStockMember_zrYVICl4YiQ9" title="Antidilutive securities excluded from computation of earnings per share">228,333 unissued restricted stock and $<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pd" title="Antidilutive securities excluded from computation of earnings per share">725,000 of convertible debt securities that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the six months ended April 30, 2025.

4649857

295000

250000

50000

3591721

228333

725000

Stock-Based Compensation All stock-based payments are recognized in the financial statements based on their fair values. The Company periodically issues stock options and stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $31,000 and $42,000 for the three months ended April 30, 2026 and 2025, respectively and approximately $50,000 and $48,000 for the six months ended April 30, 2026 and 2025, respectively. The research and development costs primarily relate to the filing and approval of IND applications and the performance of clinical trials.

31000 42000 50000 48000

Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one — Quoted market prices in active markets for identical assets or liabilities; Level two — Inputs other than level one inputs that are either directly or indirectly observable such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level three — Unobservable inputs that are supported by little or no market activity and developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of convertible notes approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

Recently Issued Accounting Pronouncements In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on its financial statement disclosures. We have reviewed all accounting pronouncements recently issued by the FASB and the SEC. The authoritative pronouncements that we have already adopted did not have a material effect on our financial condition, results of operations, cash flows or reporting thereof, and except as otherwise noted above, we do not believe that any of the authoritative pronouncements that we have not yet adopted will have a material effect upon our financial condition, results of operations, cash flows or reporting thereof.

NOTE 3 – GOING CONCERN The unaudited accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company incurred net losses of $997,000 for the six months ended April 30, 2026 and used $609,000 of cash from operating activities during that period. In addition, the Company had an accumulated deficit of $68,731,000 at April 30, 2026 and stockholders’ equity of $712,000 at April 30, 2026. The Company had working capital of $155,000 at April 30, 2026. United States Food and Drug Administration (“FDA”) regulations which were announced in November 2017 and which became effective in May 2021 require that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products (“HCT/Ps”) can only be sold pursuant to an approved biologics license application (“BLA”). Notwithstanding the above, certain states, including Florida (SB 1768) have approved legislation that permits the use and sale of products that would otherwise be restricted under current FDA regulations. The Company has not obtained any opinion or ruling regarding the Company’s operations and whether the processing, sales and distribution of the products it currently produces would be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s. As a result of the above, the Company’s efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless (a) the Company’s ability to process, sell and distribute the products currently being produced or developed in the future are not restricted; and/or (b) additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products. The Company does not have any assets to pledge for the purpose of borrowing additional capital. In addition, the Company relies on its ability to produce and sell products it manufactures that are subject to changing technology and regulations that it currently sells and distributes to its customers. The Company’s current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all. In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (i) the Company is able to continue to produce products or obtain products under supply arrangements which are in compliance with current and future regulatory guidelines; (ii) the Company will be able to establish a stabilized source of revenues, including efforts to expand sales internationally and the development of new product offerings and/or designations of products; (iii) obligations to the Company’s creditors are not accelerated; (iv) the Company’s operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations; (v) the Company is able to continue its research and development activities, particularly in regards to remaining compliant with the FDA and ongoing safety and efficacy of its products; and/or (vi) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources. There is no assurance that the products we currently produce will not be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s and/or the Company will be able to complete its revenue growth strategy. There is no assurance that the Company’s research and development activities will be successful or that the Company will be able to timely fund the required costs of those activities. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant efforts since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues. If revenues do not increase and stabilize, if the Company’s ability to process, sell and/or distribute the products currently being produced or developed in the future are restricted, and/or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws. As of April 30, 2026, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s October 31, 2025 financial statements, has expressed substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

-997000

-609000

-68731000

712000

155000

NOTE 4 – INVENTORIES <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zaIjj0nHT1D3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of inventories</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_492_20260430_zLd9hCJ1uTff" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_490_20251031_zbRKkSr103G4" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pp0d_maINzVga_zAVRfwSZb7p2" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Raw materials and supplies</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">262,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">208,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0d_maINzVga_zTnSRycYdMRg" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Finished goods</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">424,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">215,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_409_eus-gaap--InventoryNet_iTI_pp0d_mtINzVga_ztzrDyIY5SB8" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total inventories</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">686,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">423,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zaIjj0nHT1D3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of inventories</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_492_20260430_zLd9hCJ1uTff" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_490_20251031_zbRKkSr103G4" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pp0d_maINzVga_zAVRfwSZb7p2" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Raw materials and supplies</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">262,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">208,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0d_maINzVga_zTnSRycYdMRg" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Finished goods</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">424,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">215,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_409_eus-gaap--InventoryNet_iTI_pp0d_mtINzVga_ztzrDyIY5SB8" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total inventories</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">686,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">423,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

262000

208000

424000

215000

686000

423000

NOTE 5 – PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zmp2uF5qdtk5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of property and equipment</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Finance lease equipment</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">156,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">156,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Manufacturing equipment</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">856,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">778,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,012,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">934,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Less: accumulated depreciation</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(403,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(365,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total property and equipment, net</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">609,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">569,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> Depreciation expense totaled $19,000 and $16,000 for the three months ended April 30, 2026 and 2025, respectively. Depreciation expense totaled $38,000 and $34,000 for the six months ended April 30, 2026 and 2025, respectively.

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zmp2uF5qdtk5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of property and equipment</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Finance lease equipment</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">156,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">156,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Manufacturing equipment</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">856,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">778,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,012,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">934,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Less: accumulated depreciation</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(403,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(365,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total property and equipment, net</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">609,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">569,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

156000

856000

778000

1012000

934000

403000

365000

609000

569000

19000

16000

38000

34000

NOTE 6 – EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--SchedulrOfEquityInNonMarketableSecuritiesAffiliatedEntityTableTextBlock_ziyqnd7MoHb1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of equity in non marketable securities</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260430_zZGtjACstCp5" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20251031_z3BUqfxGCzI2" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_404_ecustom--EquityInNonmarketableSecurities_iI_pp0d_maMSNz2jA_zaOXCYiuCLQl" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Equity in non-marketable securities</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">145,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40B_ecustom--ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities_iI_pp0d_maMSNz2jA_zfhaw8484wKa" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Reserve on carrying value of investment in non-marketable securities</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(145,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr> <tr id="xdx_407_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0d_mtMSNz2jA_zQPXp9LZy946" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Equity in non-marketable securities</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> As of October 31, 2025, the Company invested $145,000 in the non-marketable equity securities of Exotropin (“Exotropin”), a privately-held skin-care formulator in an effort to accelerate the Company’s development of expertise with respect to the skincare industry and the potential supply of the Company’s products in future formulations. As of October 31, 2025, the Company had recorded total reserves against the carrying value of its investment of Exotropin of $145,000, based on the limited financial history of Exotropin to date and the lack of any information to ascertain the fair value of Exotropin. On March 31, 2026 (“Execution Date”) the Company, Greyt Ventures, LLC (“Greyt”), a principal shareholder of the Company and Skycrest Holdings, LLC, a former principal shareholder of the Company (“Skycrest” and, together with the Company and Greyt, each a “Seller” and collectively “Sellers”), AML Group Holdings, LLC, a Florida limited liability company (“AML”) BRM Holdings LLC a Delaware limited liability company (“BRM”), B4U2 LLC a Delaware limited liability company (“B4U2”), and GFourz Holdings LLC an Illinois limited liability company (“Gfourz” and, together with AML, BRM, and B4U2 each a “Purchaser” and collectively “Purchasers”), and Exotropin (Exotropin together with Purchasers and Sellers, each a “Party” and collectively the “Parties”) entered into a purchase and sales agreement (“Agreement”) whereby each Seller agreed to sell to Purchasers, and Purchasers agreed to purchase from each Seller, all of such Seller’s Membership Units in Exotropin, including, without limitation, the corresponding rights, powers, benefits, and privileges relating thereto or arising therefrom, and the obligations thereunder, pursuant to Exotropin’s Limited Liability Company Agreement (as amended to date, the “LLC Agreement”) relating to the Membership Units (collectively, the “Membership Interests”), for the aggregate cash consideration of $2,788,000 (the “Purchase Price”). The Parties agreed to allocate the Purchase Price as follows: $376,000 to the Company in respect of the Company’s Membership Interests; $1,206,000 to Greyt in respect of Greyt’s Membership Interests; and $1,206,000 to Skycrest in respect of Skycrest’s Membership Interests (the foregoing amounts allocated to each of the Sellers, an “Allocated Purchase Price”). The closing of the purchase and sale of the Membership Interests, including payment of the Allocated Purchase Price took place on April 7, 2026 (“Closing”). At the Closing, (i) each Seller delivered to the Purchasers an Assignment of its Membership Interests (ii) Purchasers paid the Allocated Purchase Price to each Seller by wire transfer, (iii) Exotropin delivered to the Company a dismissal notice dismissing its pending lawsuit against the Company with prejudice and with each party agreeing to bear its own fees and costs (see Note 13) and (iv) the Company returned all remaining inventory of Exotropin held by Seller as of the date of the Agreement. In addition, under the terms of the Agreement, effective as of the Closing, and without any further action of the Company or Exotropin, the Sales Representative Agreement (“Sales Agreement”) between the Company and Exotropin was terminated and was of no further force or effect and the Company and none of the provisions of the Sales Agreement survive termination of the Sales Agreement. The Agreement also provided for other terms regarding non solicitation and each party provided general mutual releases. During the three months and six months ended April 30, 2026, the Company recorded a gain of $390,000 from the sale of its Exotropin interests comprised of the proceeds of $376,000 received from the sale of its interests in Exotropin and the reduction of previously recorded liabilities of $14,000. For the three months and six months ended April 30, 2026, no commissions were paid to the Company in connection with the Sales Agreement. For the three months and six months ended April 30, 2025, $19,000 and $51,000, respectively, of commissions were earned under the Sales Agreement. The commissions earned under the Sales Agreement are reflected in other income in the unaudited consolidated financial statements. <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--SchedulrOfEquityInNonMarketableSecuritiesAffiliatedEntityTableTextBlock_ziyqnd7MoHb1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of equity in non marketable securities</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260430_zZGtjACstCp5" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20251031_z3BUqfxGCzI2" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_404_ecustom--EquityInNonmarketableSecurities_iI_pp0d_maMSNz2jA_zaOXCYiuCLQl" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Equity in non-marketable securities</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">145,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40B_ecustom--ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities_iI_pp0d_maMSNz2jA_zfhaw8484wKa" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Reserve on carrying value of investment in non-marketable securities</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(145,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr> <tr id="xdx_407_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0d_mtMSNz2jA_zQPXp9LZy946" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Equity in non-marketable securities</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> 145000 -145000 145000 Exotropin’s Limited Liability Company Agreement (as amended to date, the “LLC Agreement”) relating to the Membership Units (collectively, the “Membership Interests”), for the aggregate cash consideration of $2,788,000 (the “Purchase Price”). The Parties agreed to allocate the Purchase Price as follows: $376,000 to the Company in respect of the Company’s Membership Interests; $1,206,000 to Greyt in respect of Greyt’s Membership Interests; and $1,206,000 to Skycrest in respect of Skycrest’s Membership Interests (the foregoing amounts allocated to each of the Sellers, an “Allocated Purchase Price”). 390000 376000 14000

19000

51000

NOTE 7 – FINANCE LEASE OBLIGATIONS During April 2025, the Company entered into a lease agreement for certain lab equipment in the amount of $125,000 (“Lease Agreement”). The Lease Agreement was accounted for as a finance lease obligation. Under the terms of the lease agreement, the Company is required to make 60 equal monthly payments of $1,600 plus applicable sales taxes. Under the lease agreement, the Company has the option to acquire all of the leased equipment for a nominal amount upon termination of the lease. The annual interest rate charged in connection with the lease is 2.7%. Lease payments and depreciation of the leased equipment began during June 2025, the date that the lease equipment was installed and became operational. The leased equipment is being depreciated over their estimated useful lives of <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250430__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zuU328fc2A5e" title="Estimated useful lives of leased equipment">15 years beginning from the date it became operational. During June 2025, the Company entered into a lease agreement for certain lab equipment in the amount of $15,000 (“Lease Agreement”). The Lease Agreement was accounted for as a finance lease obligation. Under the terms of the lease agreement, the Company is required to make 36 equal monthly payments of $500 plus applicable sales taxes. Under the lease agreement, the Company has the option to acquire all of the leased equipment for a nominal amount upon termination of the lease. The annual interest rate charged in connection with the lease is 8.0%. Lease payments and depreciation of the leased equipment began during June 2025, the date that the lease equipment was installed and became operational. The leased equipment is being depreciated over it estimated useful life of <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zwLVxPNR6MX6" title="Estimated useful lives of leased equipment">3 years beginning from the date it became operational. As of April 30, 2026, $96,000 was due under finance lease obligations lease through 2030, of which $33,000 is current.

125000

1600

0.027

P15Y

15000

500

0.080

P3Y

96000

33000

NOTE 8 – RELATED PARTY TRANSACTIONS For the three months ended April 30, 2026 and 2025 and the six months ended April 30, 2026 and 2025, the Company sold a total of approximately $<span id="xdx_905_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_c20260201__20260430__dei--LegalEntityAxis__custom--ManagementServicesOrganizationMember_pp0p" title="Proceeds from Sale of Other Productive Assets">30,000, $<span id="xdx_907_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_c20250201__20250430__dei--LegalEntityAxis__custom--ManagementServicesOrganizationMember_pp0p" title="Proceeds from Sale of Other Productive Assets">24,000, $<span id="xdx_906_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_c20251101__20260430__dei--LegalEntityAxis__custom--ManagementServicesOrganizationMember_pp0p" title="Proceeds from Sale of Other Productive Assets">30,000 and $<span id="xdx_909_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_c20241101__20250430__dei--LegalEntityAxis__custom--ManagementServicesOrganizationMember_pp0p" title="Proceeds from Sale of Other Productive Assets">24,000, respectively, of product to a management services organization (“MSO”) that provides administrative services and contracts for medical supplies for several medical practices, of which Dr. George Shapiro, the Company’s Chief Medical Officer and a member of the board of directors has an indirect economic interest in the parent company that owns the MSO. For the three months and six months ended April 30, 2025, $19,000 and $51,000, respectively, of commissions were earned under the Sales Agreement.

30000

24000

30000

24000

19000

51000

NOTE 9 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zbhs9ZtyTBVg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of account payable and accrued expenses</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_498_20260430_zqrVyhO9EPs4" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_497_20251031_zQ0bXmBj3xya" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_402_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0d_maAPAALzLRp_zlOetsjzjkke" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accrued payroll related liabilities</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">667,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">667,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40B_ecustom--LabEquipmentAndSuppliesPayables_iI_pp0d_maAPAALzLRp_zABdIyn6sdQ2" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Lab equipment and supplies payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">154,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">120,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_404_ecustom--ClinicalTrialPayables_iI_pp0d_maAPAALzLRp_zmDvdnoAhG5b" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Clinical trial and research payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">637,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">634,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40E_ecustom--LegalFeesPayables_iI_pp0d_maAPAALzLRp_z9qPoF29p4eh" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Legal fees payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">277,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">244,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_405_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0d_maAPAALzLRp_zphRtcHdJ0G" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other professional fees payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">147,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">121,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_pp0d_maAPAALzLRp_zgkNquHvGAY6" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Interest payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40B_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0d_maAPAALzLRp_z8LmDnVFPAgd" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Royalty payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40E_ecustom--AccruedCommissionsPayable_iI_pp0d_maAPAALzLRp_zh4Z1bPO09Cf" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accrued commissions payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">83,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">37,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_404_ecustom--ConstructionPayables_iI_pp0d_maAPAALzLRp_zNHiGAyOaP23" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Construction payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40F_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pp0d_maAPAALzLRp_zlJ3ljywQvBh" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Other payables and accrued expenses</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">107,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">47,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pp0d_mtAPAALzLRp_zqJtfamxH2ll" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total Accounts Payable and Accrued Expenses</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,143,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,980,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zbhs9ZtyTBVg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of account payable and accrued expenses</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_498_20260430_zqrVyhO9EPs4" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_497_20251031_zQ0bXmBj3xya" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_402_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0d_maAPAALzLRp_zlOetsjzjkke" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accrued payroll related liabilities</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">667,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">667,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40B_ecustom--LabEquipmentAndSuppliesPayables_iI_pp0d_maAPAALzLRp_zABdIyn6sdQ2" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Lab equipment and supplies payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">154,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">120,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_404_ecustom--ClinicalTrialPayables_iI_pp0d_maAPAALzLRp_zmDvdnoAhG5b" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Clinical trial and research payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">637,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">634,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40E_ecustom--LegalFeesPayables_iI_pp0d_maAPAALzLRp_z9qPoF29p4eh" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Legal fees payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">277,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">244,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_405_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0d_maAPAALzLRp_zphRtcHdJ0G" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other professional fees payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">147,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">121,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_pp0d_maAPAALzLRp_zgkNquHvGAY6" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Interest payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40B_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0d_maAPAALzLRp_z8LmDnVFPAgd" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Royalty payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40E_ecustom--AccruedCommissionsPayable_iI_pp0d_maAPAALzLRp_zh4Z1bPO09Cf" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Accrued commissions payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">83,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">37,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_404_ecustom--ConstructionPayables_iI_pp0d_maAPAALzLRp_zNHiGAyOaP23" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Construction payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40F_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pp0d_maAPAALzLRp_zlJ3ljywQvBh" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Other payables and accrued expenses</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">107,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">47,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pp0d_mtAPAALzLRp_zqJtfamxH2ll" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total Accounts Payable and Accrued Expenses</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,143,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,980,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

667000

154000 120000 637000 634000 277000 244000

147000

121000

12000

1000

50000

100000

83000 37000 9000 9000

107000

47000

2143000

1980000

NOTE 10 – NOTES PAYABLE <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfDebtTableTextBlock_zOBqRhziiVNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of notes payable</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_498_20260430_zv7Hy4IngM68" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_497_20251031_z5xKq797eObk" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_402_eus-gaap--ConvertibleDebt_iI_pp0d_maLTDCzZJd_zrU1Q4IPu7tf" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Convertible Promissory Note</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">250,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">250,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0d_di_msLTDCzZJd_zW1l4I13os8f" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Unamortized discount</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(3,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(7,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr> <tr id="xdx_408_eus-gaap--LongTermDebtCurrent_iTI_pp0d_mtLTDCzZJd_zNMZzrgph112" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total Notes Payable</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">247,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">243,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> Convertible Promissory Notes The Convertible Promissory Note is due September 30, 2026. Interest on the Convertible Promissory Note is 8.0% payable annually and together with the principal amount on the maturity date. The Convertible Promissory Note may be prepaid by the Company, in whole, but not in part, at any time prior to the Maturity Date, subject to payment of a premium of 10%, provided that the Company gives the holder fifteen (15) days business notice prior to prepayment, during which period, the investor may elect to convert the Note and accrued but unpaid interest thereon into Shares at a conversion price equal to 80% of the average of the daily VWAP of the Shares (as defined in the Note) for twenty consecutive (<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z7D0IZj91F26" title="Trading days">20) trading days ending on the date the Company gives the holder of the Convertible Promissory Note notice of prepayment. The Holder of the Convertible Promissory Note will have the right, at any time during the period commencing on April 1, 2024 and ending on the earliest to occur of the Maturity Date, the date of a Prepayment or the date of an automatic conversion, to convert the Convertible Promissory Note in whole, but not in part, and accrued interest thereon into Shares at a conversion price equal to 80% of the average of the daily VWAP of the Shares (as defined in the Convertible Promissory Note) for twenty consecutive (20) trading days ending on the date the investor gives the Company a notice of conversion, subject to a minimum conversion price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20260430__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pd" title="Debt Instrument, Convertible, Conversion Price">6.00 per Share. In addition, the Convertible Promissory Note and accrued but unpaid interest thereon will automatically convert into Shares in the event that prior to the Maturity Date, the Company consummates a “Qualified Financing” or a “Qualified Sale” (as defined in the Convertible Promissory Note) at a conversion price equal to 80% of the offering price of Shares sold in the Qualified Financing or 80% of the purchase price per Share to be received by stockholders following consummation of a Qualified Sale. In connection with the issuance of the Convertible Promissory Notes, the Company recorded a discount in the amount of $72,000. The discount is being amortized over the term of Convertible Promissory Notes. For the three months ended April 30, 2026 and 2025, $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20260201__20260430__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Amortization of Debt Discount (Premium)">2,000 and $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20250201__20250430__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Amortization of Debt Discount (Premium)">6,000, respectively, of the discounts recorded in connection with the issuance of the Convertible Promissory Notes have been amortized. For the six months ended April 30, 2026 and 2025, $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20251101__20260430__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Amortization of Debt Discount (Premium)">4,000 and $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20241101__20250430__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Amortization of Debt Discount (Premium)">12,000, respectively, of the discounts recorded in connection with the issuance of the Convertible Promissory Notes have been amortized. At April 30, 2026, the unamortized debt discount recorded in connection with the issuance of the Convertible Promissory Note was $3,000. In addition, as of April 30, 2026, the Convertible Promissory Notes were convertible into 41,667 shares of common stock.

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfDebtTableTextBlock_zOBqRhziiVNi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of notes payable</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_498_20260430_zv7Hy4IngM68" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_497_20251031_z5xKq797eObk" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_402_eus-gaap--ConvertibleDebt_iI_pp0d_maLTDCzZJd_zrU1Q4IPu7tf" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Convertible Promissory Note</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">250,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">250,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0d_di_msLTDCzZJd_zW1l4I13os8f" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Unamortized discount</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(3,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(7,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> </tr> <tr id="xdx_408_eus-gaap--LongTermDebtCurrent_iTI_pp0d_mtLTDCzZJd_zNMZzrgph112" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total Notes Payable</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">247,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">243,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

250000

3000

7000

247000

243000

2026-09-30

0.080

6.00

72000

2000

6000

4000

12000

3000

41667

NOTE 11 – CAPITAL STOCK Common Stock 2021 Plan In September 2021, the Company adopted the 2021 Equity Incentive Plan (“2021 Plan”). The 2021 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, and Performance Shares (an “Award”) to any person who is an employee or director of, or consultant to the Company. The maximum aggregate number of shares that may be issued pursuant to all Awards was <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20210901__20210930__us-gaap--PlanNameAxis__custom--N2021PlanMember_zFBC8hIRRx35" title="Maximum aggregate number of shares">1,250,000 shares. On June 6, 2023, the Company’s board of directors and stockholders holding a majority of the Company’s voting power, approved an increase in the number of shares of the Company’s common stock reserved for issuance under the Company’s 2021 Plan from <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20210901__20210930__us-gaap--PlanNameAxis__custom--N2021PlanMember_pd" title="Maximum aggregate number of shares">1,250,000 shares to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20230601__20230606__us-gaap--PlanNameAxis__custom--N2021PlanMember_pd" title="Maximum aggregate number of shares">2,500,000 shares. On June 10, 2026, the Company’s board of directors approved an increase in the number of shares of the Company’s common stock reserved for issuance under the Company’s 2021 Plan from <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20230601__20230606__us-gaap--PlanNameAxis__custom--N2021PlanMember_z4abELbsKgD9" title="Maximum aggregate number of shares">2,500,000 shares to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20260601__20260610__us-gaap--PlanNameAxis__custom--N2021PlanMember_pd" title="Maximum aggregate number of shares">7,500,000 shares. The 2021 Plan is administered by (a) the board of the directors of the Company; or (b) a committee designated by the board, which Committee shall be constituted in such a manner as to satisfy the applicable laws and to permit such grants and related transactions under the Plan to be exempt from Section 16(b) of the Exchange Act in accordance with Rule 16b-3. Once appointed, such committee shall continue to serve in its designated capacity until otherwise directed by the board. The board of directors may at any time amend, suspend, or terminate the Plan; provided, however, that no such amendment shall be made without the approval of the Company’s shareholders to the extent such approval is required by applicable laws. As of April 30, 2026, a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20260430__us-gaap--PlanNameAxis__custom--N2021PlanMember_pd" title="Number of shares, outstanding">2,054,895 Awards (net of 1,379,524 Awards redeposited for future issuance) have been awarded under the 2021 Plan and remain issued and outstanding. There are <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20260430__us-gaap--PlanNameAxis__custom--N2021PlanMember_pd" title="Shares available for issuance">445,105 remaining shares that available for issuance under the 2021 Plan. Sale Of Common Stock On July 25, 2025, ZEO entered into a subscription agreement (“Subscription Agreement”) with a single accredited investor (the “Investor”). Pursuant to which the Investor agreed to purchase <span id="xdx_902_ecustom--NumberOfCommonStockPurchased_c20250701__20250725__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--CounterpartyNameAxis__us-gaap--InvestorMember_pd" title="Number of common stock purchased">250,000 shares of our common stock (the “Shares”) in a private transaction for an aggregate purchase price of $1,000,000 (the “Purchase Price”). The Shares were to be issued and sold and the Purchase Price paid in ten (10) equal monthly installments commencing on August 1, 2025 and ending on May 1, 2026. As of October 31, 2025, 75,000 shares have been sold for an aggregate of $300,000 in accordance with the Subscription Agreement. On November 1, 2026, an additional 25,000 shares were sold for $100,000 in accordance with the Subscription Agreement. On February 10, 2026, the Subscription Agreement was amended whereby the total number of Shares to be purchased under the Subscription Agreement was reduced to 100,000 Shares and no further shares are issuable. As of April 30, 2026, a total of 100,000 shares have been sold for an aggregate amount of $400,000 pursuant to the Subscription Agreement. The above securities were offered and sold to the investors in accordance with the exemption from registration afforded by Section 4(a)(2) of and/or Rule 506(b) of Regulation D under the Securities Act. Private Offering – Common Stock and Warrants From November 2025 to April 2026, the Company sold 7.4 Units to fifteen investors for an aggregate purchase price of $1,850,000 in a private transaction. Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis. In connection with the sale of the Units, the Company issued 462,500 shares of common stock and 462,500 warrants to purchase shares of common stock. The above securities were offered and sold to the investors in accordance with the exemption from registration afforded by Section 4(a)(2) of and/or Rule 506(b) of Regulation D under the Securities Act. Restricted Stock Awards On December 1, 2025, the Company entered into a consulting agreement with a third party to provide certain market engagement and investor relations consulting services to the Company. Pursuant to the Consulting Agreement, the Company issued the consultant <span id="xdx_90D_ecustom--NumberOfSharesAwarded_c20251130__20251201__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--CounterpartyNameAxis__custom--ConsultantMember_pd" title="Number of shares awarded">10,000 restricted shares of common stock of the Company, 5,000 shares which vested and were issued on the agreement date and 5,000 Shares which vested on the 90th day after the agreement date. The 10,000 grant of shares were valued at $2.05 per share, the closing price of the common stock of the Company on the effective date of the grant. The Company will amortize $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20251130__20251201__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--CounterpartyNameAxis__custom--ConsultantMember_pp0p" title="Stock-based compensation">21,000 of stock-based compensation expense in accordance with the vesting periods. The Company recorded a total of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20260201__20260430__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--CounterpartyNameAxis__custom--ConsultantMember_pp0p" title="Stock-based compensation">11,000 and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20251101__20260430__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--CounterpartyNameAxis__custom--ConsultantMember_pp0p" title="Stock-based compensation">21,000 of stock-based compensation expense based on the grant date fair value of these shares during the three and six months ended April 30, 2026, respectively. On December 23, 2025, in consideration for his performance, the Company awarded an employee of the Company, a bonus in the form of a restricted stock grant under the Company’s 2021 Plan of <span id="xdx_90A_ecustom--NumberOfSharesAwarded_c20251202__20251223__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Number of shares awarded">25,000 shares of the Company’s common stock, to vest as to 12,500 shares on the date of the grant and the remaining 12,500 shares on the first anniversary of the award date. The 25,000 grant of shares were valued at $2.66 per share, the closing price of the common stock of the Company on the effective date of the grant. The Company will amortize $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20251202__20251223__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Stock-based compensation">66,000 of stock-based compensation in accordance with the vesting periods. The Company recorded a total of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20260201__20260430__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Stock-based compensation">8,000 and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20251101__20260430__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Stock-based compensation">44,000 of stock-based compensation expense based on the grant date fair value of these shares during the three and six months ended April 30, 2026, respectively. On January 14, 2026, pursuant to the Company’s 2021 Plan, the Company’s Compensation Committee (“Comp Board”) awarded <span id="xdx_909_ecustom--NumberOfSharesAwarded_c20260101__20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__srt--CounterpartyNameAxis__custom--IanBothwellMember_zvqnIvDw3vL6" title="Number of shares awarded">175,000 shares of the Company’s common stock to Ian Bothwell, the Company’s Chief Executive Officer and <span id="xdx_900_ecustom--NumberOfSharesAwarded_c20260101__20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--TitleOfIndividualAxis__custom--ChiefMedicalOfficerMember__srt--CounterpartyNameAxis__custom--DrGeorgeShapiroMember_pd" title="Number of shares awarded">175,000 shares of the Company’s common stock to Dr. George Shapiro, the Company’s Chief Medical Officer. The Comp Board also approved the grant of <span id="xdx_902_ecustom--NumberOfSharesAwarded_c20260101__20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--GreytVenturesLLCMember_pd" title="Number of shares awarded">175,000 shares of common stock of the Company to Greyt Ventures LLC, a principal shareholder of the Company in consideration of consulting services rendered to the Company. The 525,000 grant of shares were valued at $2.66 per share, the closing price of the common stock of the Company on the effective date of the grant. The Company will amortize $1,395,000 of stock-based compensation expense over the one-year vesting term. The Company recorded $450,000 and $508,000 of stock-based compensation expense during the three and six months ended April 30, 2026, respectively. The shares have not yet vested but have been issued as of April 30, 2026. In connection with Dr. Kisiday’s Employment Agreement, Dr. Kisiday was granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260114__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_zhwrGtcCkLrl">50,000 shares of common stock under the 2021 Plan. The stock grant vests as to 20,000 shares on the first anniversary of the of the Employment Agreement and 30,000 shares on the second anniversary of the Employment Agreement. The 50,000 grant of shares were valued at $<span id="xdx_902_eus-gaap--SharePrice_c20260114__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_pd">2.74 per share, the closing price of the common stock of the Company on the effective date of the Employment Agreement. The Company will amortize $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20260101__20260114__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_pp0p">137,000 of stock-based compensation expense over the two-year vesting term. Effective March 23, 2026, Dr. Kisiday’s employment was terminated and the <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20260101__20260114__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_pd">50,000 stock grant was forfeited. During the period February 2026 to April 2026, in consideration for agreeing to join the Company’s medical advisory board or as a consultant, the Company issued to ten individuals an aggregate of 167,500 shares of unregistered common stock valued between $1.80 and $2.45 per share, the closing price of the common stock of the Company on the respective grant dates. 10,000 of the shares vested immediately and the remaining 157,500 shares vest over periods up to a maximum of 3 years. The Company will record $342,000 of stock-based compensation expense based on the grant date fair value of these shares over the respective vesting terms. The Company recorded a total of $48,000 of stock-based compensation expense based on the grant date fair value of these shares during the three and six months ended April 30, 2026. During the six months ended April 30, 2026, <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20251101__20260430__srt--CounterpartyNameAxis__custom--ConsultantMember_zdpXS02WxRW6" title="Option vested">20,833 shares that were granted in 2024 vested, of which $152,000 of stock based compensation expense was recognized during the six months ended April 30, 2026. The shares have not yet been issued as of April 30, 2026. In addition, 125,000 shares granted prior October 31, 2025 were forfeited due to termination and/or failure to satisfy service performance conditions of the respective agreements. A summary of unvested restricted stock activity for the six months ended April 30, 2026 are presented below: <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zancnQ5Es7g3" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Schedule of non vested share activity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Non-vested Shares</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Grant Date Value</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Non-vested Shares at October 31, 2025</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zrhDqtTx60be" title="Number of nonvested shares outstanding at beginning">228,333</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_905_ecustom--FairValueOfNonvestedShares_iS_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zfjHjLFuBe46" title="Fair value of nonvested shares outstanding at beginning">451,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_z30QKewMie28" title="Weighted- average grant date value, outstanding at beginning">2.05</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Shares Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_pd" title="Non-vested shares granted">777,500</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1,961,000</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_pd" title="Weighted- average grant date value, non-vested shares granted">2.57</td> <td style="text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_z8BqutA9cHi" title="Vested">(103,333</td> <td style="white-space: nowrap; text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(773,000</td> <td style="white-space: nowrap; text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_iN_di_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zzuR6NMJGgpi" title="Weighted- average grant date value, vested">-</td> <td style="text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Expired/Forfeited</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zPYCVljpxp8c" title="Expired/forfeited">(175,000</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--FairValueOfExpiredforfeitedShares_iN_pp0d_di_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zGskVvLCjdC7" title="Fair value of expired/forfeited shares">(357,000</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_pd" title="Weighted- average grant date value, expired/forfeited">2.05</td> <td style="text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt">Non-vested Shares at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zkQqASGywVrc" title="Number of nonvested shares, outstanding at end">727,500</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--FairValueOfNonvestedShares_iE_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zabYWO9HQagd" title="Fair value of nonvested shares, outstanding at end">1,282,000</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zGsNY2NnvEW9" title="Weighted- average grant date value, outstanding at end">2.47</td> <td style="text-align: left; padding-bottom: 1.25pt"> </td> </tr> </table> There was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20260430__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_pp0p" title="Unamortized compensation">1,282,000 of unamortized compensation associated with unvested stock grants outstanding as of April 30, 2026 that will be amortized over their respective remaining service periods.

1250000

2500000

7500000

2054895

1379524

445105

250000

75000

300000

25000

100000

400000

7.4

1850000

Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis.

462500

462500 10000

2.05

21000

11000

21000

25000

2.66

66000

8000

44000

175000 175000 175000 525000

2.66

1395000

450000

508000

50000

2.74

137000

50000

167500

1.80

2.45

48000

20833

152000

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zancnQ5Es7g3" style="font: 10pt Times New Roman; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Schedule of non vested share activity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <th style="text-align: left; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Non-vested Shares</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Grant Date Value</th> <th style="text-align: center; padding-bottom: 0.5pt"> </th> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">Non-vested Shares at October 31, 2025</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zrhDqtTx60be" title="Number of nonvested shares outstanding at beginning">228,333</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_905_ecustom--FairValueOfNonvestedShares_iS_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zfjHjLFuBe46" title="Fair value of nonvested shares outstanding at beginning">451,000</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_z30QKewMie28" title="Weighted- average grant date value, outstanding at beginning">2.05</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Shares Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_pd" title="Non-vested shares granted">777,500</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1,961,000</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_pd" title="Weighted- average grant date value, non-vested shares granted">2.57</td> <td style="text-align: left"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_z8BqutA9cHi" title="Vested">(103,333</td> <td style="white-space: nowrap; text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(773,000</td> <td style="white-space: nowrap; text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_iN_di_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zzuR6NMJGgpi" title="Weighted- average grant date value, vested">-</td> <td style="text-align: left"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 0.5pt">Expired/Forfeited</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zPYCVljpxp8c" title="Expired/forfeited">(175,000</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--FairValueOfExpiredforfeitedShares_iN_pp0d_di_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zGskVvLCjdC7" title="Fair value of expired/forfeited shares">(357,000</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_pd" title="Weighted- average grant date value, expired/forfeited">2.05</td> <td style="text-align: left; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top; padding-bottom: 1.25pt">Non-vested Shares at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zkQqASGywVrc" title="Number of nonvested shares, outstanding at end">727,500</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--FairValueOfNonvestedShares_iE_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zabYWO9HQagd" title="Fair value of nonvested shares, outstanding at end">1,282,000</td> <td style="white-space: nowrap; text-align: left; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20251101__20260430__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockMember_zGsNY2NnvEW9" title="Weighted- average grant date value, outstanding at end">2.47</td> <td style="text-align: left; padding-bottom: 1.25pt"> </td> </tr> </table>

228333

451000

2.05

777500

1961000

2.57

103333

773000

175000

357000

2.05

727500

1282000

2.47

1282000

NOTE 12 – STOCK OPTIONS AND WARRANTS The Company has issued option securities under its Incentive Plan and warrants entitling the holder to purchase shares of its common stock at specified prices and for specified exercise periods. Options: A summary of the Company’s option activity for the six months ended April 30, 2026 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfjcDnn8cqk1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Schedule of stock options activity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- average Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining Contractual Term (years)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Outstanding at October 31, 2025</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1VpJencjV49" title="Number of shares, outstanding beginning balance">1,172,482</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqu0rcP1d63k" title="Weighted-average exercise price, outstanding beginning balance">2.91</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zw13BXjvu963" title="Remaining contractual term (years), outstanding beginning balance">6.61</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuUu4XIHG4S6" title="Aggregate intrinsic value, outstanding beginning balance">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, granted">7,790</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, granted">4.50</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGl3ujiqhcXd" title="Remaining contractual term (years), granted">5.00</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Expired/Forfeited</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zf4WAQ4XBQA1" title="Number of shares, expired/forfeited">(85,877</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, expired/forfeited">2.74</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_za0TMbHWDeae" title="Remaining contractual term (years), expired/forfeited">3.14</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Outstanding at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfOSDdG022Yf" title="Number of shares outstanding ending balance">1,094,395</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyeFzPQ3FbMf" title="Weighted-average exercise price outstanding ending balance">2.94</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverage_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyVXlesbemE4" title="Remaining contractual term (years) outstanding ending balance">6.33</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPfqSL130P89" title="Aggregate intrinsic value outstanding ending balance">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Exercisable at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, exercisable">1,071,964</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercisable">2.91</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEXQlHayogbd" title="Remaining contractual term (years) outstanding, exercisable">6.39</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, exercisable">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> During the six months ended April 30, 2026, under its Incentive Plan, the Board approved the granting of options to certain employees to purchase 7,790 shares of its common stock. The options vest annually over 3 years, expire five years from the date of grant and had an aggregate fair value of $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20251101__20260430__srt--TitleOfIndividualAxis__custom--EmployeesMember_pp0p" title="Aggregate fair value">20,000 at the date of grant. The Company valued the options using a Black-Scholes option pricing model with the following assumptions: <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zLgmhHR51WW8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 1)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of assumptions</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Exercise prices</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise prices">4.50</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Expected dividends</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDAdMuyUvSGd" title="Expected dividends">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUtGDI8Gzys1" title="Expected volatility">179</td> <td style="text-align: left; white-space: nowrap">%</td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Risk free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgieBknrvDEg" title="Risk free interest rate">3.79</td> <td style="text-align: left; white-space: nowrap">%</td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Expected term of options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkDwHQeU3MR3" title="Expected life of options">5.0 years</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> </table> Options totaling <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20251101__20260430__srt--TitleOfIndividualAxis__custom--EmployeesMember_pd" title="Options forfeited">85,877 that were previously issued to employees that are no longer employed by the Company as of April 30, 2026, were forfeited. During the three months ended April 30, 2026 and 2025, the Company amortized $9,000 and $265,000, respectively, of stock compensation costs associated with options vesting during the period. During the six months ended April 30, 2026 and 2025, the Company amortized $194,000 and $514,000, respectively, of stock compensation costs associated with options vesting during the period. There was approximately $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Unamortized compensation costs">57,000 of unamortized compensation associated with options outstanding as of April 30, 2026 that will be amortized over their respective remaining service periods. Warrants: A summary of the Company’s warrant activity for the six months ended April 30, 2025 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfWarrantActivityTableTextBlock_zR6jQiBgm2xd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 2)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Schedule of warrant activity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- average Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining Contractual Term (years)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Outstanding at October 31, 2025</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRj3FwFS0Inf" title="Number of shares, outstanding beginning balance">3,092,962</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z80BbI3CKimc" title="Weighted-average exercise price, outstanding beginning balance">3.62</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWlFe3LAtSj7" title="Remaining contractual term (years), outstanding beginning balance">6.24</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4IcvKNydXia" title="Aggregate intrinsic value, outstanding beginning balance">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">462,500</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, granted">4.00</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingGrantedContractualTerm2_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlzQ6vtghVoh" title="Remaining contractual term, granted">4.90</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Expired/Forfeited</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, expired/forfeited">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, expired/forfeited">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Outstanding at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmVbyK0tqDWd" title="Number of shares outstanding ending balance">3,555,462</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkXpegmxAZJh" title="Weighted-average exercise price outstanding ending balance">3.67</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zia2Gu03Ip3" title="Remaining contractual term (years) outstanding ending balance">5.59</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4NqhqgmIVD" title="Aggregate intrinsic value outstanding ending balance">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Exercisable at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, exercisable">3,055,462</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercisable">3.80</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJ6UyMavDHhk" title="Remaining contractual term (years) outstanding, exercisable">6.18</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercisable">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> As described in Note 11, from November 2025 to April 2026, the Company sold 7.4 Units to fifteen investors for an aggregate purchase price of $1,850,000 in a private transaction. Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis. In connection with the sale of the Units, the Company issued 462,500 shares of common stock and 462,500 warrants to purchase shares of common stock. During the three months ended April 30, 2026 and 2025, the Company amortized $0 and $810,000, respectively, of stock compensation costs associated with warrants vesting during the period. During the six months ended April 30, 2026 and 2025, the Company amortized $215,000 and $1,620,000, respectively, of stock compensation costs associated with warrants vesting during the period. Included in the table above is approximately $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Unamortized compensation costs">1,122,000 of unamortized compensation associated with 500,000 warrants outstanding as of April 30, 2026. The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable based upon meeting certain conditions provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The fair value of the warrants was determined to be $1,122,000. The Company will begin to amortize the $1,122,000 fair value when management estimates the vesting conditions are probable of being achieved. All stock compensation expense is classified under general and administrative expenses in the consolidated statements of operations.

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfjcDnn8cqk1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Schedule of stock options activity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- average Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining Contractual Term (years)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Outstanding at October 31, 2025</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1VpJencjV49" title="Number of shares, outstanding beginning balance">1,172,482</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqu0rcP1d63k" title="Weighted-average exercise price, outstanding beginning balance">2.91</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zw13BXjvu963" title="Remaining contractual term (years), outstanding beginning balance">6.61</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuUu4XIHG4S6" title="Aggregate intrinsic value, outstanding beginning balance">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, granted">7,790</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, granted">4.50</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGl3ujiqhcXd" title="Remaining contractual term (years), granted">5.00</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Expired/Forfeited</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zf4WAQ4XBQA1" title="Number of shares, expired/forfeited">(85,877</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt">)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, expired/forfeited">2.74</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_za0TMbHWDeae" title="Remaining contractual term (years), expired/forfeited">3.14</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Outstanding at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfOSDdG022Yf" title="Number of shares outstanding ending balance">1,094,395</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyeFzPQ3FbMf" title="Weighted-average exercise price outstanding ending balance">2.94</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverage_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyVXlesbemE4" title="Remaining contractual term (years) outstanding ending balance">6.33</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPfqSL130P89" title="Aggregate intrinsic value outstanding ending balance">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Exercisable at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, exercisable">1,071,964</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercisable">2.91</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEXQlHayogbd" title="Remaining contractual term (years) outstanding, exercisable">6.39</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, exercisable">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

1172482

2.91

P6Y7M9D

7790

4.50

P5Y

85877

2.74

P3Y1M20D

1094395

2.94

P6Y3M29D

1071964

2.91

P6Y4M20D

7790

20000

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zLgmhHR51WW8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 1)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of assumptions</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Exercise prices</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Exercise prices">4.50</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Expected dividends</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDAdMuyUvSGd" title="Expected dividends">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUtGDI8Gzys1" title="Expected volatility">179</td> <td style="text-align: left; white-space: nowrap">%</td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Risk free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgieBknrvDEg" title="Risk free interest rate">3.79</td> <td style="text-align: left; white-space: nowrap">%</td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Expected term of options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkDwHQeU3MR3" title="Expected life of options">5.0 years</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> </table>

4.50

1.79

0.0379

P5Y

85877

9000

265000

194000

514000

57000

<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfWarrantActivityTableTextBlock_zR6jQiBgm2xd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 2)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Schedule of warrant activity</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- average Exercise Price</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining Contractual Term (years)</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Outstanding at October 31, 2025</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRj3FwFS0Inf" title="Number of shares, outstanding beginning balance">3,092,962</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z80BbI3CKimc" title="Weighted-average exercise price, outstanding beginning balance">3.62</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWlFe3LAtSj7" title="Remaining contractual term (years), outstanding beginning balance">6.24</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4IcvKNydXia" title="Aggregate intrinsic value, outstanding beginning balance">-</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">462,500</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, granted">4.00</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingGrantedContractualTerm2_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlzQ6vtghVoh" title="Remaining contractual term, granted">4.90</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercised">-</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 0.5pt">Expired/Forfeited</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, expired/forfeited">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, expired/forfeited">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Outstanding at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmVbyK0tqDWd" title="Number of shares outstanding ending balance">3,555,462</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkXpegmxAZJh" title="Weighted-average exercise price outstanding ending balance">3.67</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zia2Gu03Ip3" title="Remaining contractual term (years) outstanding ending balance">5.59</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4NqhqgmIVD" title="Aggregate intrinsic value outstanding ending balance">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Exercisable at April 30, 2026</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, exercisable">3,055,462</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercisable">3.80</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJ6UyMavDHhk" title="Remaining contractual term (years) outstanding, exercisable">6.18</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20260430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercisable">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table>

3092962

3.62

P6Y2M26D

462500

4.00

P4Y10M24D

3555462

3.67

P5Y7M2D

3055462

3.80

P6Y2M4D

7.4

1850000

462500

810000

215000

1620000

1122000

500000

The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable based upon meeting certain conditions provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The fair value of the warrants was determined to be $1,122,000. The Company will begin to amortize the $1,122,000 fair value when management estimates the vesting conditions are probable of being achieved.

NOTE 13 – COMMITMENTS AND CONTINGENCIES Deferred Revenue Amounts received by the Company for future purchases of inventory or for products that have yet to be delivered to the customers as of April 30, 2026 and October 31, 2025 are reflected in the Company’s balance sheet as deferred revenues and were comprised of the following: <table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--ScheduleOfDeferredRevenueTableTextBlock_zA3wEoyefxs1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of deferred revenue</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49D_20260430_zi2GyY5qHZFl" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_492_20251031_zciuFCXkpY9k" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_405_ecustom--Advances_iI_pp0d_maDRzDae_z3F5qOpZd9Oe" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Advances On Future Purchases Of Inventory</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">74,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">145,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40A_ecustom--SalesToCustomersNotYetDelivered_iI_pp0d_maDRzDae_zXIfJ1yM6n4" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Sales To Customers Not Yet Delivered</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">597,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">453,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_404_eus-gaap--DeferredRevenue_iTI_pp0d_mtDRzDae_zxyGRCCckSGi" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total Deferred Revenue</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">671,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">598,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> Employment Agreement Dr. John D. Kisiday, Ph.D. Effective January 23, 2026, Dr. Kisiday was appointed the Company’s Chief Technology Officer. Dr. Kisiday’s employment agreement (“Employment Agreement”) provides for a base salary of $<span id="xdx_900_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260123__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_pp0p" title="Base salary">175,000 and a stock grant of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260123__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_pd" title="Number of options granted">50,000 shares of common stock under our 2021 Incentive Plan. The stock grant vests as to 20,000 shares on the first anniversary of the of the Employment Agreement and 30,000 shares on the second anniversary of the Employment Agreement, contingent upon Dr. Kisiday’s continued employment with the Company. In addition, if Dr. Kisiday brought a commercially viable new product and/or business opportunity to the Company outside the existing scope of the Company’s current line of business, Dr. Kisiday will be entitled to receive additional compensation therefor. Dr. Kisiday’s employment with the Company was “At Will” meaning that his employment with the Company and his Employment Agreement may be terminated by the Company at any time, for any reason or for no reason at all and with or without “Cause” (as defined in the Employment Agreement). Notwithstanding the foregoing, if at any time after the first ninety (90) days of the term, the Company terminates Dr. Kisiday’s employment without Cause or Dr. Kisiday terminates his employment with the Company for “Good Reason” (as defined in the Employment Agreement), Dr. Kisiday will be entitled to receive severance in an amount equal to one quarter (1/4) month’s salary for each successive three (3) months of employment completed. Dr. Kisiday’s employment agreement contains customary confidentiality, non-competition and non-solicitation covenants. On March 21, 2026, as provided for under the Employment Agreement, the Company provided Dr. Kisiday with notice that his employment was being terminated effective March 23, 2026. As a result of Dr. Kisiday’s termination, the stock grant was forfeited in full effective March 23, 2026. Purchase Commitments During July 2025, the Company entered into an exclusive supply agreement (“Supply Agreement”) with a third-party contract manufacturer (“CDMO”) in connection with the manufacturing and processing of certain biological products (“CDMO Products”) that the Company that the Company intends to sell to third party medical providers. Under the terms of the Supply Agreement, the Company prepaid $500,000. Under the terms of the Supply Agreement, the deposits will be applied against the actual CDMO Products that are released to the Company. The Company has agreed to make a minimum of 8 purchase orders within specified periods based on satisfactory release of prior productions of the CDMO Products (“Minimum Purchase Orders”). In connection with each purchase order, the Company is required to have minimum deposits paid to the CDMO equal to 50% of the value of the purchase order. The Supply Agreement may be extended by the Company based on submitting a minimum amount of additional purchase orders after the Minimum Purchase Orders have been released. As of April 30, 2026 and October 31, 2025, outstanding advances were $267,000 and $225,000, respectively that is included in prepaid expenses in the accompanying condensed consolidated balance sheets. Legal Matters Neurovive Holding Co., LLC On January 26, 2026, Neurovive Holding Co., LLC (“Neurovive”), Paragon Medical Group, LLC (“Paragon”), and Dr. David Buechner (“Dr. Buechner,” and together with Neurovive and Paragon, “Plaintiffs”), filed a complaint in the Circuit Court of Benton County, Arkansas Civil Division against the Company asserting claims for breach of contract, breach of fiduciary duty, misappropriation of trade secrets, fraud, promissory estoppel, unjust enrichment and conversion (“Complaint”). Plaintiffs are seeking preliminary and permanent injunctive relief and compensatory damages. The litigation stems from a previous arrangement whereby Plaintiffs and the Company had sought to jointly pursue a proposed clinical trial (“Venture”) based on Plaintiffs agreeing to provide the necessary funding for the Venture (“Funding Obligations”). After a prolonged unsuccessful effort to secure the Funding Obligations, the Plaintiffs unilaterally elected to terminate further efforts to pursue the Venture. The case was removed to the United States District Court for the Western District of Arkansas, Fayetteville Division, Case No. 5:26-cv-05055. On March 30, 2026, the Company filed a Motion to Transfer Venue pursuant to 28 U.S.C. § 1404(a), seeking transfer of the action to the United States District Court for the Southern District of Florida, Fort Lauderdale Division. The motion is now fully briefed and the parties await a ruling from the Court. We are unable to express an opinion as to the possible outcome of this matter. The Company’s disputes all allegations and intends to vigorously pursue all available legal remedies. Dr. Golub The Company’s employment agreement with Dr. Howard Golub, its former Chief Science Officer (“Golub Employment Agreement”) had an initial term that ended May 31, 2024. The Golub Employment Agreement was not renewed and accordingly, the Golub Employment Agreement expired and the employment of Dr. Golub by the Company ended on May 31, 2024. On November 19, 2024, Dr. Golub (“Plaintiff”), filed a complaint in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida against the Company, alleging a breach of contract as a result of the Company’s failure to pay Plaintiff severance in the amount of $150,000 in connection with the non-renewal of Golub Employment Agreement. During June 2026, the parties entered into an agreement settling the matter and the action will be dismissed with prejudice. Exotropin On August 15, 2025, the Company terminated the Sales Agreement for cause. Exotropin filed a complaint (Case No. CACE-25-013178, in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida) against the Company for declaratory judgment on August 29, 2025, concerning the parties’ June 19, 2024, Amended and Restated Sales Representative Agreement, seeking declarations related to termination and the survival/enforceability of certain restrictive and other clauses. On November 6, 2025, the Company moved to dismiss Exotropin’s complaint. The Company filed counterclaims on November 17, 2025. On January 7, 2026, Exotropin filed a First Amended Complaint. On April 6, 2026, the parties filed a Joint Notice of Settlement with the Court. On April 13, 2026, the parties filed a Joint Stipulation of Dismissal With Prejudice, dismissing the action and all claims, counterclaims, and defenses asserted therein with prejudice, with each party bearing its own attorneys’ fees, costs, and expenses. BioXtex In June 2025, BioXtek sought to terminate the Binding MOU and the Joint Venture for alleged breaches by the Company, which the Company contested. As the Company and BioXtek were not able to amicably resolve the dispute, on December 17, 2025, the Company commenced an action against BioXtek (Case No. CACE-25-019364, in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida) and filed an amended complaint on January 5, 2026, asserting claims for breach of contract and implied covenant, fraudulent inducement, violation of the Florida Deceptive Unfair Trade Practices Act, equitable accounting, and declaratory judgment. The Company seeks damages for expectancy/consequential losses, equitable relief, and fees. On May 27, 2026, BioXtek filed a Motion to Dismiss the Amended Complaint. No hearing has been set on the Motion to Dismiss. The Company intends to oppose the Motion to Dismiss. Mediation has been scheduled for June 11, 2026. The Company continues to evaluate its legal options and intends to protect its rights under the Binding MOU and the Joint Venture. Other In addition to the foregoing, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.

<table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--ScheduleOfDeferredRevenueTableTextBlock_zA3wEoyefxs1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Schedule of deferred revenue</td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49D_20260430_zi2GyY5qHZFl" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="text-align: left"> </td> <td id="xdx_492_20251031_zciuFCXkpY9k" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td></tr> <tr style="background-color: #FFFFFF; vertical-align: bottom"> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2026</td> <td style="padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">October 31, 2025</td> <td style="padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_405_ecustom--Advances_iI_pp0d_maDRzDae_z3F5qOpZd9Oe" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Advances On Future Purchases Of Inventory</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">74,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">145,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_40A_ecustom--SalesToCustomersNotYetDelivered_iI_pp0d_maDRzDae_zXIfJ1yM6n4" style="background-color: #FFFFFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Sales To Customers Not Yet Delivered</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">597,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">453,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_404_eus-gaap--DeferredRevenue_iTI_pp0d_mtDRzDae_zxyGRCCckSGi" style="background-color: #CCEEFF; vertical-align: bottom"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Total Deferred Revenue</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">671,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">598,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt"> </td> </tr> </table> 74000 145000 597000 453000

671000

598000

175000

50000

267000

225000

150000

NOTE 14 – SEGMENT INFORMATION Under ASC 280, Segment Reporting, operating segments are defined as components of an enterprise where discrete financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one reportable and operating segment. The measure of segment assets is reported on the balance sheet as total assets. The Company’s Chief Executive Officer, who is also the CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance. Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM for the three months and six months ended April 30, 2026 and 2025. <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zGFQ6FHkUR6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details)"> <tr style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of other Income</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260201__20260430_zdvwYWvePJ0l" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49E_20250201__20250430_z9v6Krdkaqa9" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_491_20251101__20260430_zqlVOnmeo1pa" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20241101__20250430_ztdwbMQuaSh3" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended April 30,</th> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended April 30,</th> <th style="padding-bottom: 0.5pt"> </th> </tr> <tr style="vertical-align: bottom"> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</th> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</th> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</th> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</th> <th style="padding-bottom: 0.5pt"> </th> </tr> <tr id="xdx_40E_eus-gaap--Revenues_maNILzVGp_zLA79GgWXYgl" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,581,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">1,149,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,027,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,239,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_407_eus-gaap--CostOfGoodsAndServicesSold_iN_pp0d_di_msNILzVGp_zwMT0OxPM3di" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cost of goods sold</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(526,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(256,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(807,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(447,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_402_eus-gaap--SalariesAndWages_iN_pp0d_di_msNILzVGp_zahQzG0Vuov7" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Salaries & consulting fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(839,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(716,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,562,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,425,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_405_eus-gaap--ProfessionalFees_iN_pp0d_di_msNILzVGp_zNvLQmyCRGy2" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(295,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(137,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(455,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(283,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_404_ecustom--Commissions_iN_di_msNILzVGp_zMQqZw5dgbI5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Commissions</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(279,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(91,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(465,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(178,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_407_eus-gaap--MarketingExpense_iN_pp0d_di_msNILzVGp_zWCIrFOS25t8" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Marketing</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(238,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(73,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(342,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(114,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_403_eus-gaap--ShareBasedCompensation_iN_pp0d_di_msNILzVGp_zt0JMomeJm1c" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Stock based compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(590,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,096,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,182,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(2,187,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_iN_pp0d_di_msNILzVGp_zyrUVoG69oYk" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Lab expenses</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(204,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(39,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(373,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(41,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_msNILzVGp_z12SqFql9k35" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Research & development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(31,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(42,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(50,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(48,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_40F_eus-gaap--InsuranceTax_iN_di_msNILzVGp_zm6Y43OkIUMk" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Insurance</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(47,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(80,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(109,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(106,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_405_eus-gaap--OfficersCompensation_iN_pp0d_di_msNILzVGp_zxeEENASOz2e" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Office expenses & other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(45,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(13,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(72,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(57,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpense_maNILzVGp_zI92XkN5uVD5" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other income (expenses), net</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(22,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">13,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_400_ecustom--GainOnSaleOfExotropinInterests_iN_di_msNILzVGp_z036BhQP0LUi" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Gain on sale of Exotropin interests</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">390,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">390,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pp0d_mtNILzVGp_zNIMYg2nmMu5" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Net loss</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(145,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(1,391,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(997,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(2,634,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> </tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zGFQ6FHkUR6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details)"> <tr style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Schedule of other Income</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260201__20260430_zdvwYWvePJ0l" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49E_20250201__20250430_z9v6Krdkaqa9" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_491_20251101__20260430_zqlVOnmeo1pa" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20241101__20250430_ztdwbMQuaSh3" style="text-align: right"> </td> <td style="text-align: left; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended April 30,</th> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended April 30,</th> <th style="padding-bottom: 0.5pt"> </th> </tr> <tr style="vertical-align: bottom"> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</th> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</th> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</th> <th style="padding-bottom: 0.5pt"> </th> <th style="padding-bottom: 0.5pt"> </th> <th colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</th> <th style="padding-bottom: 0.5pt"> </th> </tr> <tr id="xdx_40E_eus-gaap--Revenues_maNILzVGp_zLA79GgWXYgl" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,581,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">1,149,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,027,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,239,000</td> <td style="width: 1%; text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_407_eus-gaap--CostOfGoodsAndServicesSold_iN_pp0d_di_msNILzVGp_zwMT0OxPM3di" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Cost of goods sold</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(526,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(256,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(807,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(447,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_402_eus-gaap--SalariesAndWages_iN_pp0d_di_msNILzVGp_zahQzG0Vuov7" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Salaries & consulting fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(839,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(716,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,562,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,425,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_405_eus-gaap--ProfessionalFees_iN_pp0d_di_msNILzVGp_zNvLQmyCRGy2" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(295,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(137,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(455,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(283,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_404_ecustom--Commissions_iN_di_msNILzVGp_zMQqZw5dgbI5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Commissions</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(279,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(91,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(465,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(178,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_407_eus-gaap--MarketingExpense_iN_pp0d_di_msNILzVGp_zWCIrFOS25t8" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Marketing</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(238,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(73,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(342,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(114,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_403_eus-gaap--ShareBasedCompensation_iN_pp0d_di_msNILzVGp_zt0JMomeJm1c" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Stock based compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(590,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,096,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,182,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(2,187,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_iN_pp0d_di_msNILzVGp_zyrUVoG69oYk" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Lab expenses</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(204,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(39,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(373,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(41,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_iN_pp0d_di_msNILzVGp_z12SqFql9k35" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Research & development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(31,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(42,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(50,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(48,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_40F_eus-gaap--InsuranceTax_iN_di_msNILzVGp_zm6Y43OkIUMk" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Insurance</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(47,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(80,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(109,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(106,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_405_eus-gaap--OfficersCompensation_iN_pp0d_di_msNILzVGp_zxeEENASOz2e" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Office expenses & other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(45,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(13,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(72,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(57,000</td> <td style="text-align: left; white-space: nowrap">)</td> </tr> <tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpense_maNILzVGp_zI92XkN5uVD5" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Other income (expenses), net</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(22,000</td> <td style="text-align: left; white-space: nowrap">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,000</td> <td style="text-align: left; white-space: nowrap"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">13,000</td> <td style="text-align: left; white-space: nowrap"> </td> </tr> <tr id="xdx_400_ecustom--GainOnSaleOfExotropinInterests_iN_di_msNILzVGp_z036BhQP0LUi" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 0.5pt">Gain on sale of Exotropin interests</td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">390,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">390,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> <td style="padding-bottom: 0.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 0.5pt"> </td> </tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_pp0d_mtNILzVGp_zNIMYg2nmMu5" style="vertical-align: bottom; background-color: #FFFFFF"> <td style="text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.25pt">Net loss</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(145,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(1,391,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(997,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> <td style="padding-bottom: 1.25pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(2,634,000</td> <td style="text-align: left; white-space: nowrap; padding-bottom: 1.25pt">)</td> </tr> </table>

2581000

1149000

4027000

2239000

526000

256000

807000

447000

839000

716000

1562000

1425000

295000

137000

455000

283000

279000 91000 465000 178000

238000

73000

342000

114000

590000

1096000

1182000

2187000

204000

39000

373000

41000

31000

42000

50000

48000

47000

80000

109000

106000

45000

13000

72000

57000

-22000

3000

13000

-390000 -390000

-145000

-1391000

-997000

-2634000

NOTE 15 – SUBSEQUENT EVENTS Sale of Units During May 2026 and June 2026, the Company sold an additional <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260501__20260615__srt--CounterpartyNameAxis__custom--TwoInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pd" title="Number of units sold">0.8 Units to two investors for an aggregate purchase price of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0d_c20260501__20260615__srt--CounterpartyNameAxis__custom--TwoInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5ZutHICgRkd" title="Aggregate purchase price">200,000. In connection with the sale of the Units, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260501__20260615__srt--CounterpartyNameAxis__custom--TwoInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pd" title="Number of common stock issued">50,000 shares of common stock and <span id="xdx_908_ecustom--NumberOfWarrantsPurchased_c20260501__20260615__srt--CounterpartyNameAxis__custom--TwoInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pd" title="Number of warrants purchased">50,000 warrants to purchase shares of common stock. The above securities were offered and sold to the investors in accordance with the exemption from registration afforded by Section 4(a)(2) of Rule 506(b) of Regulation D under the Securities Act. Related Party On May 12, 2026, Greyt, Dr. Shapiro, Mr. Bothwell and the Company formed Serephon LLC (“Serephon”), a Delaware limited liability company. The Serephon operating agreement provides for Serephon to seek to (a) own and operate clinics providing regenerative and longevity-related clinical services through licensed physicians and other appropriately credentialed clinical personnel in jurisdictions where it is permitted by applicable law and licensed to do so; and (b) operate in other jurisdictions as a management services organization providing non-clinical administrative, operational, advisory, technology, marketing, management, equipment, procurement, and other lawful support services to physician-owned medical practices and other lawful healthcare-adjacent businesses, while not engaging in the practice of medicine. The Board of Directors determined that the Company had no intention of engaging in the clinical services being offered by Serephon other than described below. In connection with the Serephon business, the Company will agree to supply biologic products to Serephon and/or Serephon’s owned and participating clinics, in exchange for an initial fifty percent (50%) Class A limited liability company membership interest (48 units) in Serephon, with the remaining Class A limited liability company membership interests owned equally by Greyt (16 units), Dr. Shapiro (16 Units) and Mr. Bothwell (16 Units). Equity Awards On June 10, 2026, the Company awarded the following options to purchase shares of our common stock (“Options”) under the 2021 Plan: (a) The Company awarded Options under the 2021 Plan for 625,000 shares of common stock, to each of Greyt Ventures LLC, a principal stockholder and consultant to the Company, Ian Bothwell, the Company’s Chief Executive Officer and Chief Financial Officer and a member of the board of directors, and George Shapiro, the Company’s Chief Medical Officer and a member of the board of directors. The Options are fully vested as of the award date, are exercisable on a “cashless basis” for a period of ten (10) years from the award date at an exercise price of $1.67 per share, and are subject to the other terms and conditions of the 2021 Plan. (b) The Company awarded Options under the 2021 Plan for 625,000 shares of common stock to each of Greyt Ventures LLC, Ian Bothwell and George Shapiro (“Incentive Options”). The Incentive Options vest in full upon the achievement of certain performance milestones, are exercisable on a “cashless basis” during the period commencing on the date they vest and ending ten (10) years from the award date at an exercise price of $1.67 per share, and are subject to the other terms and conditions of the 2021 Plan. The Incentive Options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company’s common stock outstanding on a fully diluted basis. (c) The Company awarded Options under the 2021 Plan for 80,000 shares of common stock to Chuck Bretz a non-executive director of the Company and an aggregate of 77,500 shares of common stock to certain other Company employees and a consultant. The Options are fully vested as of the grant date, are exercisable for a period of five (5) years from the award date at an exercise price of $1.67 per share, and are subject to the other terms and conditions of the 2021 Plan.

0.8

200000

50000

50000 false false false false